Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine

Click to increase image sizeClick to decrease image size AcknowledgmentsThe authors thank all the physicians and staff at the hospital who participated in this study.Disclosure statementNo potential conflict of interest was reported by the author(s).Data availability statementThe data are available from the corresponding author on reasonable request.Additional informationFundingThis research was funded by the Japan Society for the Promotion of Science (JSPS) KAKENHI [grant number JP20K16095].